- Home
- XXII vs SCNI Comparison
XXII vs SCNI Comparison
Compare XXII & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- SCNI
- Stock Information
- Founded
- XXII 1998
- SCNI 2003
- Country
- XXII United States
- SCNI Israel
- Employees
- XXII N/A
- SCNI N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XXII Health Care
- SCNI Health Care
- Exchange
- XXII Nasdaq
- SCNI Nasdaq
- Market Cap
- XXII 2.8M
- SCNI 3.1M
- IPO Year
- XXII N/A
- SCNI N/A
- Fundamental
- Price
- XXII $5.10
- SCNI $3.51
- Analyst Decision
- XXII
- SCNI
- Analyst Count
- XXII 0
- SCNI 0
- Target Price
- XXII N/A
- SCNI N/A
- AVG Volume (30 Days)
- XXII 2.5M
- SCNI 8.1K
- Earning Date
- XXII 11-12-2024
- SCNI 11-22-2024
- Dividend Yield
- XXII N/A
- SCNI N/A
- EPS Growth
- XXII N/A
- SCNI N/A
- EPS
- XXII N/A
- SCNI 8.20
- Revenue
- XXII $17,304,000.00
- SCNI $452,000.00
- Revenue This Year
- XXII $56.94
- SCNI N/A
- Revenue Next Year
- XXII $2.98
- SCNI N/A
- P/E Ratio
- XXII N/A
- SCNI $0.43
- Revenue Growth
- XXII N/A
- SCNI N/A
- 52 Week Low
- XXII $3.90
- SCNI $2.23
- 52 Week High
- XXII $581.85
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- XXII 41.23
- SCNI 52.75
- Support Level
- XXII $4.80
- SCNI $3.41
- Resistance Level
- XXII $12.49
- SCNI $3.80
- Average True Range (ATR)
- XXII 2.00
- SCNI 0.18
- MACD
- XXII 0.36
- SCNI -0.00
- Stochastic Oscillator
- XXII 3.90
- SCNI 36.42
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.